Rchr
J-GLOBAL ID：202101001624004833
Update date: Oct. 18, 2024
MATSUDA Eriko
マツダ エリコ | MATSUDA Eriko
Affiliation and department：
Research theme for competitive and other funds (4)：
- 2023 - 2026 1型糖尿病の残存β細胞を保護・増殖するin vivo遺伝子治療の開発
- 2023 - 2026 浸潤・転移の骨軟部肉腫を治療可能な革新的な腫瘍溶解性ウイルス・免疫治療法の創出
- 2022 - 2025 免疫チェックポイントBispecific抗体遺伝子発現・腫瘍溶解性ウイルスの創出
- 2018 - 2021 Establishment of a new differentiation conversion method to mature pancreatic beta cells by analysis of gene expression over time during differentiation process
Papers (3)：
-
Hirotaka Kawakami, Nobuhiro Ijichi, Yuki Obama, Eriko Matsuda, Kaoru Mitsui, Yuya Nishikawaji, Maki Watanabe, Satoshi Nagano, Noboru Taniguchi, Setsuro Komiya, et al. An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy. Translational research : the journal of laboratory and clinical medicine. 2024. 273. 32-45
-
Eriko Matsuda, Yuki Obama, Ken-Ichiro Kosai. Safe and low-dose but therapeutically effective adenovirus-mediated hepatocyte growth factor gene therapy for type 1 diabetes in mice. Life sciences. 2021. 268. 119014-119014
-
Kaoru Mitsui, Tomoyuki Takahashi, Kanako Ide, Eriko Matsuda, Ken-Ichiro Kosai. Optimization of adenoviral gene transfer in human pluripotent stem cells. Biochemical and biophysical research communications. 2021. 541. 78-83
Association Membership(s) (2)：
Return to Previous Page
